Summit Securities Group’s NanoViricides NNVC Stock Holding History

Summit Securities Group’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-8	Closed	–	–	556
2015 Q1	$0	Buy	+8	New	+$427	﹤0.01%	563

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Summit Securities Group's NNVC Position: Q2 2015 in Review

Summit Securities Group sold out of NanoViricides (NNVC) in Q2 2015, closing a stake of 8 shares.

Summit Securities Group first reported a position in NNVC in Q1 2015 and held it in 1 quarter. The position peaked at $0 in Q1 2015. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2015.

Summit Securities Group reported no remaining NanoViricides position as of Q2 2015 after selling out during the quarter.
Summit Securities Group sold 8 NanoViricides shares in Q2 2015.
Summit Securities Group first reported a position in NanoViricides in Q1 2015 and held it in 1 quarter.
Summit Securities Group's NanoViricides position peaked at $0 in Q1 2015.
48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2015.

Based on Summit Securities Group's 13F filing for Q2 2015, filed 5 Aug 2015.